Inclusion Criteria:

- Age >= 18 years

- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2

- NOTE: Patients with a history of metastatic cancer or an ECOG performance status of 2 must have laboratory (lab) work completed =< 28 days prior to registration

- Pain, numbness, tingling or other symptoms of CIPN of >= 3 months (90 days) duration for which the patient is seeking an intervention

- Neurotoxic chemotherapy must have been completed >= 3 months (90 days) prior to registration and there must be no further planned neurotoxic -chemotherapy for > 2 months after registration Note: The study is limited to those with taxane- and/or platinum-based neuropathy

- Patient must note tingling, numbness or pain symptoms of at least a four out of ten =< 7 days prior to registration.

- Note: On a 0-10 scale where zero was 'no problem' and ten being 'as bad a problem that could be imagined': how much of a problem has numbness, tingling, and/or
pain in your fingers and/or toes been in the past week?

- Patient must be able to speak, read and comprehend English

- For women of childbearing potential only, a negative urine or serum pregnancy test done =< 14 days prior to registration is required

- A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)

- NOTE: If the urine test cannot be confirmed as negative, a serum pregnancy test will be required

- Life expectancy >= 6 months

- Platelet count > 100,000/mm^3

- NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =< 28 days prior to registration

- Absolute neutrophil count (ANC) >= 1,000/mm^3

- NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =< 28 days prior to registration

- Hemoglobin > 11 g/dL

- NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =< 28 days prior to registration

- Serum transaminase (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) =< 1.2 x upper limit of normal (ULN)

- NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have these labs completed =< 28 days prior to registration

- Alkaline phosphatase =< 1.2 x ULN

- NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =< 28 days prior to registration

- Serum creatinine =< 1.2 x ULN

- NOTE: Patients with a history of metastatic cancer or an ECOG performance status of 2 must have this lab completed =< 28 days prior to registration

- Able to swallow oral medication

- Provide written informed consent =< 28 days prior to registration

Exclusion Criteria:

- Currently receiving neurotoxic chemotherapy for a second cancer or recurrence of the primary cancer

- Impaired decision-making capacity (such as with a diagnosis of dementia or memory loss)

- Evidence of residual cancer, per routine clinical practice-based parameters

- Comorbid conditions:

- Previous diagnosis of diabetic or another non chemotherapy induced peripheral neuropathy

- Previous history of peripheral neuropathy prior to receiving neurotoxic chemotherapy

- Neuropathy from human immunodeficiency virus (HIV) infection. Note: Patients with HIV infections are eligible as long as they do not have a neuropathy from their
viral illness

- Concurrent use of a cannabis product  (tetrahydrocannabinol [THC] and/or cannabidiol
[CBD]). Patients should have discontinued these products >= 4 weeks prior to registration

- Current or previous use of PEA

- Currently receiving or planning to start any of the following agents: opioids, duloxetine, gabapentin or pregabalin. Patients are eligible if they discontinue these medications >= 1 week prior to registration

- Any of the following because the study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are
unknown:

- Pregnant persons

- Nursing persons

- Persons of childbearing potential who are unwilling to employ adequate contraception

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/30/23. Questions regarding updates should be directed to the study team contact.